Antituberculosis drugs: reducing efflux = increasing activity
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (3) , 592-599
Abstract
No abstract availableKeywords
Funding Information
- European Union (FP7-260872)
This publication has 75 references indexed in Scilit:
- The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug CandidatesAntimicrobial Agents and Chemotherapy, 2012
- Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosisPLOS ONE, 2012
- A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsCurrent Opinion in Pharmacology, 2011
- Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugsJournal of Antimicrobial Chemotherapy, 2011
- Efflux‐Pump–Derived Multiple Drug Resistance to Ethambutol Monotherapy inMycobacterium tuberculosisand the Pharmacokinetics and Pharmacodynamics of EthambutolThe Journal of Infectious Diseases, 2010
- A Balancing Act: Efflux/Influx in Mycobacterial Drug ResistanceAntimicrobial Agents and Chemotherapy, 2009
- Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in BacteriaClinical Microbiology Reviews, 2006
- Role of mycobacterial efflux transporters in drug resistance: an unresolved questionFEMS Microbiology Reviews, 2006
- Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamicsJournal of Antimicrobial Chemotherapy, 2003